SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

One-year results from the CLASP IID trial and registry showed outstanding results in patients with significant symptomatic degenerative mitral regurgitation (DMR) for Pascal, Edwards Lifesciences Corp ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...

Edwards Lifesciences can say two things about its Pascal Precision Valve Repair System. The first is that the technology has FDA approval and the second is that in a study, the device showed its ...